A phase I study of anti-CD3 x cetuximab-armed activated T cells, low dose IL-2 [aldesleukin], and GM-CSF [sargramostim] for EGFR [epidermal growth factor receptor]-positive, advanced non-small cell lung cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin (Primary) ; Sargramostim (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics
- 25 Mar 2015 Biomarkers information updated
- 18 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 23 Apr 2013 Planned end date changed from 1 Feb 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.